1. Home
  2. ORGO vs IPHA Comparison

ORGO vs IPHA Comparison

Compare ORGO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Organogenesis Holdings Inc.

ORGO

Organogenesis Holdings Inc.

HOLD

Current Price

$1.31

Market Cap

181.4M

Sector

Health Care

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.54

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ORGO
IPHA
Founded
1985
1999
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
181.4M
165.3M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
ORGO
IPHA
Price
$1.31
$1.54
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$2.00
★ $6.67
AVG Volume (30 Days)
★ 605.5K
51.6K
Earning Date
11-05-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1600.00
N/A
EPS
N/A
★ N/A
Revenue
★ $564,169,000.00
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
$37.55
$143.06
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 17.04
N/A
52 Week Low
$1.28
$1.18
52 Week High
$7.08
$2.71

Technical Indicators

Market Signals
Indicator
ORGO
IPHA
Relative Strength Index (RSI) 32.51 27.90
Support Level N/A $1.34
Resistance Level $2.69 $1.57
Average True Range (ATR) 0.06 0.10
MACD 0.01 -0.02
Stochastic Oscillator 13.64 0.00

Price Performance

Historical Comparison
ORGO
IPHA

About ORGO Organogenesis Holdings Inc.

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: